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Postoperative morbidity after cardiopulmonary b pass most commonly man- 
ifests as bleeding diatheses or pulmonary dysfunction. The pathophysiology 
has been attributed to the activation of cellular and humoral components of 
blood after contact with an artificial surface. Development of a surface that 
would be nonthrombogenic and also would constitute a less potent inflamma- 
tory stimulus would therefore be beneficial. In the following experiments, we 
evaluated the heparin-bonded Carmeda Bioactive Surface (Medtronics Car- 
diopulmonary, Anaheim, Calif.) in an in vitro model of extracorporeal circu- 
lation at standard-dose h parin (5 U/ml), to examine the effects of the surface 
treatment on activation of blood elements, and at reduced-dose heparin (1 
U/ml), to determine whether surface-bound heparin would serve as an effective 
anticoagulant. During the initial recirculation period, platelet counts in the 
Carmeda (n = 12) circuits were preserved at both doses of heparin and 
compared with control values (n = 12): At 5 U/ml, control 36% - 4% (mean _ 
standard error of the mean) versus Carmeda 81% - 5%; at 1 U/ml, 43% +- 3% 
versus 61% --- 10%, expressed as a percent of baseline at 30 minutes, p < 0.05. 
Furthermore, plasma levels of platelet factor 4 and/3-thromboglobulin were 
significantly reduced in the Carmeda circuits throughout the experiment: At 
heparin 5 U/ml, 2500 - 340 ng/ml versus 604 +- 191 ng/ml; at 1 U/ml, 2933 - 
275 ng/ml versus 577 - 164 ng/ml of platelet factor 4 at 2 hours (p < 0.05). The 
pattern of ~-thromboglobulin release was similar, with effects more pro- 
nounced at the lower dose of heparin. Surface modification also reduced 
leukocyte depletion (p < 0.05) and release of elastase at both concentrations of 
heparin (5 U/ml, 0.72 - 0.29 ng/ml versus 0.33 - 0.23 ng/ml; 1 U/ml, 0.85 - 
0.08 ng/ml versus 0.20 - 0.05 ng/ml, at 2 hours, p < 0.05). Moreover, as 
heparin concentration was reduced, Carmeda surface treatment significantly 
decreased generation of C3a des Arg (1 U/ml, 14,410 - 3558 ng/ml versus 3053 
-- 1039 ng/ml at 2 hours, p < 0.05). Although heparin bonding was originally 
intended to obviate the need for systemic heparinization, Carmeda treatment 
did not reduce fibrinopeptide A generation at the lower dose of heparin. In 
summary, Carmeda treatment failed to exhibit anticoagulant efficacy in this 
model; however, the data suggest that surface modification may have a role in 
ameliorating the typical inflammatory response initiated by blood contact with 
an artificial surface. (J Thorac Cardiovasc Surg 1996;111:1073-84) 
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T he evolution of cardiac surgery over the past four decades has been accompanied by a greater 
dependence on extracorporeal circulation. 1 Al- 
though the bypass circuit has undergone xtensive 
modifications ince its inception, the sequelae of 
blood-surface interactions and high-dose heparin 
therapy continue to plague cardiac surgeons. The 
clinical complications are primarily related to bleed- 
ing diatheses, to the initiation of a systemic inflam- 
matory response, or to both. Hemostatic function is 
impaired by stimulation of the intrinsic coagulation 
system, thrombocytopenia, nd platelet dysfunc- 
tion.2, 3 Continued reliance on high-dose hepariniza- 
tion not only may promote perioperative bleeding, 
but also incurs the risks associated with protamine 
reversal. 4 Neutrophil activation, in part mediated by 
the complement system, contributes to postopera- 
tive pulmonary dysfunction and prolonged ventila- 
tor dependence in susceptible patients, -7 More 
recently, interactions of the formed blood elements, 
both with each other and with the complement and 
coagulation systems, have begun to define the com- 
plexity of the surface-induced response. 
Biomaterials research has been directed toward 
the development of a nonthrombogenic surface for 
use during mechanical circulatory support. A num- 
ber of efforts have focused on heparin surface 
bonding s with the intention of eliminating or reduc- 
ing the need for systemic heparinization. Presenta- 
tion of blood to the surface has been shown to 
initiate inflammatory, hemostatic, fibrinolytic, and 
cellular cascades. 9 Moreover, this type of surface 
modification may alter these responses and thus 
prevent some of the observed clinical complications. 
We evaluated the effects of a covalently bound 
heparin surface treatment, Carmeda Bioactive Sur- 
face (Medtronic Cardiopulmonary, Anaheim, 
Calif.), in a well-established in vitro model of car- 
diopulmonary bypass. These studies were per- 
formed at full heparinization (a 5 U/ml dose of 
heparin) to determine if heparin surface treatment 
altered the pattern of platelet, leukocyte, and com- 
plement activation during simulated cardiopulmo- 
nary bypass. In addition, fibrinopeptide A levels 
were used to directly assess the anticoagulant effi- 
cacy of this surface modification during contact with 
human blood, after reduction of the exogenous 
heparin dose (1 U/ml dose of heparin). 
Mater ia l s  and  methods  
Perfusion circuits. Perfusion circuits with a surface 
area of 0.9 m 2 were assembled from standard medical- 
grade polyvinylchloride tubing, polycarbonate connectors, 
venous reservoir bags, and a 0.8 m 2 pediatric reversed 
hollow-fiber membrane oxygenator (Minimax, Medtronic). 
The entire circuit, including the venous reservoir bag, tubing, 
and oxygenator, was flushed with 100% carbon dioxide for 
15 minutes before priming. Then 400 ml of blood from a 
single donor was drawn directly into the venous reservoir bag 
containing porcine lung heparin in a dose of either 5 or 1 
U/ml and 1.65 gm of glucose. The group containing 5U/ml 
approximated the standard heparin dose used in clinical 
cardiopulmonary bypass. The reduced heparin dose, 1 U/ml, 
was chosen because it represented the lowest concentration 
of heparin that allowed recirculation through the simulated 
loop without formation of macroscopic clots. After removal 
of residual carbon dioxide gas from the venous reservoir bag, 
the remaining components of the circuit were primed by 
permitting the blood to displace the carbon dioxide in the 
tubing and oxygenator under gravity flow. Blood was recir- 
culated by a precisely shimmed, barely occlusive calibrated 
double-roller pump (Sarns, Inc., Ann Arbor, Mich.) for 2 
hours at a rate of two times the circulating volume in liters 
per minute. 1° A minimum volume of 200 ml was required for 
recirculation in this circuit, and consequently no additional 
volume was necessary to maintain the specified conditions of 
the model. Blood temperature was maintained at37 ° C. The 
oxygenator was ventilated with a 95% oxygen/5% carbon 
dioxide mixture at a rate of 1 L/min. For the experimental 
group, the surfaces of the oxygenator and all components of
the perfusion circuit were composed of heparin-bonded 
materials (Carmeda). With the exception of the surface 
treatment, the control circuits were identical. 
Blood acquisit ion and sampling protocol. These stud- 
ies were approved by the Temple University Committee 
on Human Investigations and the National Institutes of 
Health. Written and verbal consent was obtained from 
each volunteer before venipuncture. 
Blood for recirculation trials was drawn from volunteers 
who abstained from aspirin and aspirin-containing medi- 
cations for at least 2 weeks before venipuncture. Donors 
met Red Cross standards for blood donation, including a 
hematocrit value greater than 37%. All blood samples 
were drawn into syringes containing 3.8% trisodium ci- 
trate (9:1 vol/vol). Three 20 ml baseline samples were 
obtained irectly from the volunteer and were incubated 
at 37 ° C. Additional 25 ml samples were withdrawn from 
the circuit at 5 minutes, 1 hour, and 2 hours of recircula- 
tion and analyzed with the aforementioned baseline sam- 
ples. All samples were assessed immediately for platelet 
and leukocyte number and platelet reactivity to adenosine 
diphosphate (ADP). Samples to be assayed for platelet 
and leukocyte activation products, complement C3a des 
Arg (C3a), and fibrinopeptide A were processed immedi- 
ately and frozen at -70 ° C for later analysis. Additional 10 
ml blood samples were obtained at 15 and 30 minutes of 
recirculation for leukocyte and platelet counts and fibrin- 
opeptide A determinations. 
Platelet studies 
Platelet counts. Whole blood platelet counts were ob- 
tained with a Coulter ZBI Counter (Coulter Electronics, 
Inc., Hialeah, Fla.). 
Platelet aggregation. Platelet-rich plasma was prepared 
from citrated whole blood by centrifugation at150 g for 10 
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minutes at 25 ° C. After gentle aspiration of the platelet- 
rich plasma (350,000 _+ 50,000/IA), the remaining blood 
was centrifuged at 12,000 g for 5 minutes at 25 ° C in a 
microcentrifuge to obtain platelet-poor plasma with a 
platelet count less than 1000//A. 
Platelet aggregation studies were performed as de- 
scribed previously. ~1 We determined that the platelet 
release reaction was complete when ADP-induced aggre- 
gation exceeded 62% light transmission through platelet- 
rich plasma at 5 minutes. The threshold concentration of
aggregating agent was defined as the lowest logarithmic 
concentration ecessary to produce irreversible or sec- 
ond-wave aggregation, indicating that platelet granule 
release has occurred. This value was determined for the 
control baseline samples and used to test the responsive- 
ness of the recirculated platelets at each corresponding 
time point. Reactivity to ADP at the recirculation time 
point divided by its control sample was then expressed as 
percent alteration. Normal platelet reactivity was demon- 
strated in control baseline samples for all studies using 
ADP in concentrations of 1 to 5/xmol/L. 
Platelet factor 4 and [3-thromboglobulin. Citrated whole 
blood in 3 ml aliquots was transferred to plastic tubes 
containing 10% disodium ethylenediaminetetraacetic acid 
(Na 2 EDTA), theophylfine (5.4 mg/ml), and prostaglandin 
E 1 (3 × 10 -3 mol/L) and immediately centrifuged at 2000 
g for 20 minutes at 4 ° C to obtain platelet-poor plasma. 
The platelet-poor plasma was again centrifuged at 12,000 
g at room temperature for 2 minutes in a microcentrifuge. 
Plasma levels of platelet factor 4 and/3-thromboglobu- 
lin were quantitated by radioimmunoassay with specific 
tracers and antibodies (Abbot Laboratories, Chicago, Ill., 
and Amersham Corporation, Arlington Heights, Ill.), as 
previously described. 13' 14 The sensitivity of these assays is 
1 ng/ml (platelet factor 4) and 10 ng/ml (/3-thromboglob- 
ulin). 
Thromboxane B 2. Aliquots (3.7 ml) of citrated whole 
blood were transferred to a plastic tube containing Na a 
EDTA for a final concentration of 10 mmol/L andspun 
for platelet-rich plasma. Before high-speed centrifugation 
(2000 g at room temperature for 10 minutes) to prepare 
platelet-poor plasma, enough indomethacin dissolved in 
100% ethyl alcohol was added to give a final concentration 
of 10/xmol/L. 15 
Plasma levels of thromboxane B 2 were measured by 
radioimmunoassay with a specific tracer and antibody 
(New England Nuclear/Dupont, Boston, Mass.)) 6 The 
sensitivity of this assay is 25 pg/ml. 
Leukocyte count. White blood cell counts were per- 
formed on a Coulter ZBI Counter. 
Neutrophil elastase. Plasma for determination of re- 
lease of neutrophil elastase was prepared by centrifuging 
citrated whole blood at 2000 g for 20 minutes at 4 ° C. 
Neutrophil elastase levels were immunochemically 
quantitated (EM Diagnostics, Gibbstown, N.J.) by a het- 
erogeneous sandwich enzyme-linked immunosorbent as- 
say for the elastase-al-proteinase inhibitor complex. 17 In 
brief, neutrophil elastase-aa-proteinase inhibitor com- 
plex from known standards and plasma samples was 
incubated at room temperature and allowed to bind to 
antibody-coated tubes by its neutrophil elastase nd. A 
second antibody marked with alkaline phosphatase was 
then added, complexing with the exposed ch-proteinase 
inhibitor end. The enzyme activity of the immunocom- 
plexed alkaline phosphatase was measured spectrophoto- 
metrically at A405. The colored product is directly pro- 
portional to the concentration of neutrophil elastase-a 1- 
proteinase inhibitor. All unknown samples were read from 
a generated standard curve. 
C3a. C3a was determined in plasma that was rapidly 
processed by centrifugation of citrated whole blood at 
2000 g for 20 minutes at 4 ° C. 
Before quantitation of C3a by radioimmunoassay (Am- 
ersham Corporation), plasma was pretreated to prevent 
interference from the precursor C3. Both standards and 
unknown samples were allowed to react at room temper- 
ature for 30 minutes with highly specific tracer and 
antiserum. Separation of the antibody-bound fraction 
from the free fraction was effected with addition of a 
second antibody. After an additional 30-minute incuba- 
tion, separation of this antibody-bound fraction was 
achieved by the addition of isotonic saline solution and 
high-speed centrifugation i the cold. The sensitivity of 
this assay is 40 ng/ml. 18' 19 
Fibrinopeptide A. Three milliliters of citrated whole 
blood was added to an anticoagulant containing aprotonin 
to prevent spurious generation of fibrinopeptide A during 
the preparation of platelet-poor plasma by centrifugation 
at 2000 g for 20 minutes at 4 ° C. Before performance of 
the radioimmunoassay, plasma was treated with bentonite 
to remove plasma fibrinogen and prevent cross-reactivity 
with the antibody. 
Fibrinopeptide A (ByK-Sangtec Diagnostica, Dietzen- 
bach, Germany) from standards and plasma samples 
competed with radioactive-labeled fibrinopeptide A and 
antiserum. The antibody was precipitated with bound 
tracer by using a second antibody in combination with 
polyethylene glycol. 2° The amount of radioactivity bound 
to the second antibody was then measured. The lower 
limit of sensitivity for this assay is 1 ng/ml. 
Statistics. Mean, standard eviation, and standard er- 
ror of the mean were calculated for each determinant at 
each sampling point. Univariate and multivariate analyses 
of variance were used for comparison between groups 
over time. One-way analysis of variance with the Tukey 
honest significant difference (HSD) post-hoc test was used 
to evaluate specific time points. Kruskal-Wallis one-way 
analysis of variance was used to examine platelet aggre- 
gation and thromboxane B 2 data. Unless otherwise indi- 
cated, all statistical results are based on p values obtained 
by univariate and multivariate analyses of variance. A p 
value of less than 0.05 was considered significant. 21 Six 
experiments were performed in each group. 
Results 
Platelet counts. Mean platelet  counts are ex- 
pressed as a percentage of the initial p latelet  count 
obtained from basel ine samples drawn directly from 
the volunteers (Fig. 1). 
For  control  circuits using hepar in at a concentra- 
tion of 5 U/ml, p latelet  count decl ined to 36% _+ 5% 
(mean ± standard error of the mean) of basel ine at 
1076 Korn et al. 
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Fig. 1. Circulating platelet count. Mean platelet counts from whole blood are expressed as a percentage 
of baseline and are plotted against ime. Open circle, heparin 5U/ml control (n - 6); closed circle, heparin 
5 U/ml coated (n = 6); open triangle, heparin 1 U/ml control (n = 6); closed triangle, heparin 1 U/ml coated 
(n = 6). 
Table I. Alteration of ADP-induced platelet response 
Time in minutes 
Experimental 
Heparin dose group 5 60 120 
5 U/mI Control 72% ÷ 7% 68% -+ 8% 68% _+ 4% 
Carmeda 40% _+ 6% 68% -+ 5% 63% + 9% 
1 U/ml Control 72% + 9% 79% + 6% 78% _+ 5% 
Carmeda 44% _+ 9% 58% + 12% 60% _+ 8% 
Values presented are means + standard error of the mean. These data represent alteration (loss) of responsiveness of recirculated platelets relative to control 
platelets. See Materials and methods. For all time points, n = 6. 
5 minutes. Platelet counts remained epressed at 2 
hours, with a value of 54% _+ 4%. In the treated 
circuits, the platelet counts were maintained at 
72% _+ 6% of baseline after 5 minutes of extracor- 
poreal circulation. After 2 hours, the platelet counts 
decreased to levels similar to those of the untreated 
circuits (46% _+ 7%, p < 0.05 vs control). 
In the group with reduced exogenous heparin (1 
U/ml), the control circuit platelet counts decreased 
to 36% _+ 6% of baseline at 5 minutes of recircula- 
tion, with a value of 56% -+ 2% at 2 hours. Platelet 
counts at corresponding time points in the heparin- 
coated circuits were 67% _+ 10% and 45% _+ 5% 
(p < 0.05 vs control). 
Thus at a 5 U/ml heparin dose, surface treatment 
reduced platelet depletion through the initial 30- 
minute recirculation period. In contrast, with a 1 
U/ml heparin dose, platelet loss was reduced only at 
15 minutes (p < 0.05 vs control by the Tukey HSD 
post-hoc test). 
Platelet aggregation. The data depicted in Table 
I represent the platelet response to ADP-induced 
aggregation. 
Heparin coating preserved platelet reactivity early 
in the protocol, as assessed by ADP-induced aggre- 
gation in the 5 U/ml heparin group (p < 0.05 vs 
control at 5 minutes by Kruskal-Wallis one-way 
analysis of variance). However, at reduced-dose 
heparin, statistical significance was not obtained 
although a trend toward early preservation of plate- 
let function was noted. 
Platelet factor 4 and ~-thromboglobulin. In the 5 
U/ml heparin control group, the baseline level of 
platelet factor 4 was 25 _+ 4 ng/ml (Fig. 2). After 5 
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Fig. 2. Platelet factor 4. Mean plasma levels of platelet factor 4 (PF4) (mean _+ standard error of the 
mean) are plotted against ime and expressed in nanograms per milliliter. Otherwise legend is identical to 
that of Fig. 1. 
minutes of extracorporeal circulation, this value 
rose to 1505 2 254 ng/ml and reached a plateau at 
2500 _+ 340 ng/ml by 2 hours. Surface modification 
attenuated this rise in plasma platelet factor 4 levels, 
with a baseline of 46 _+ 12 ng/ml increasing to 409 + 
103 ng/rnl and 604 _+ 191 ng/ml by 5 minutes and 2 
hours, respectively (p < 0.05 vs control). 
In the control group using a 1 U/ml heparin dose, 
platelet factor 4 increased from a baseline value of 24 
_+ 3 ng/ml to 1650 _+ 219 ng/ml after 5 minutes of 
recirculation, rising to 2933 _+ 275 ng/ml at 2 hours. 
Platelet factor 4 release was markedly reduced in the 
experimental circuits, with a baseline level of 37 _ 7 
ng/ml and values of 492 _+ 86 ng/ml at 5 minutes and 
577 +_ 164 ng/ml at 2 hours (p < 0.05 vs control). 
Because platelet factor 4 possesses an affinity for 
heparin, the possibility of platelet factor 4 binding to 
the heparin surface treatment was addressed by 
corroborating the data with measurements of 
~-thromboglobulin, another a-granule marker. In 
the uncoated circuits with standard heparin dose (5 
U/ml), the initial plasma /3-thromboglobulin evels 
(Fig. 3) rose from 70 _+ 11 ng/ml to 2040 _+ 260 
ng/ml after a 5-minute recirculation period, further 
increasing to 3367 _+ 606 ng/ml at 2 hours. In 
contrast,/3-thromboglobulin in the treatment group 
only rose from 132 + 56 ng/ml to 788 _+ 178 ng/ml 
and 1167 _+ 253 ng/ml after 5 minutes and 2 hours, 
respectively (p < 0.05 vs control). 
At the 1 U/ml heparin dose,/3-thromboglobulin in 
the control group increased from 51 _+ 5 ng/ml to 
3208 + 492 ng/ml after 5 minutes of recirculation. 
/3-thromboglobulin evels peaked at 2 hours with a 
value of 5700 +_ 1109 ng/ml. Release of/3-thrombo- 
globulin was again attenuated by the heparin surface 
treatment, with an initial value of 83 _+ 13 ng/ml 
rising to only 1207 2 254 ng/ml at 5 minutes and 
1872 2 681 ng/ml at 2 hours (p < 0.05 vs control). 
Thus surface treatment was associated with a 
marked and sustained reduction of platelet a-gran- 
ule release at both doses of heparin. 
Thromboxane B 2. The data in Table II demon- 
strate minimal generation Of thromboxane in coated 
circuits at either dose of heparin. In the control 
circuits, the trend was toward generation of greater 
levels of thromboxane, particularly at the reduced 
heparin dose (1 hour and 2 hours, p < 0.05 vs 
control by Kruskal-Wallis one-way analysis of vari- 
ance). Time points examined in the 5 U/ml heparin 
groups were not significantly different. 
Leukocyte count and neutrophil elastase. Base- 
line leukocyte counts in untreated circuits with 5 
U/ml heparin (Fig. 4, A) were 6.7 2 0.5 × 10S/mm 3.
Over the ensuing 2 hours of simulated extracorpo- 
real circulation, the leukocyte counts gradually de- 
clined to 4.9 _+ 0.4 × 103/ram 3. In the heparin- 
treated circuits, leukocyte counts were preserved 
with an initial value of 6.1 2 0.7 x 103/mm 3 and 
1078 Korn et al. 
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Fig. 3. /9-Thromboglobulin. Mean plasma levels of/3-thromboglobulin (BTG) (mean _+ standard error of 
the mean) are plotted against ime and expressed innanograms per milliliter. Otherwise legend is identical 
to that of Fig. 1. 
Table II. Thromboxane B 2 generation 
Time in minutes 
Heparin Experimental 
dose group 0 5 60 120 
5 U/ml Control 426 -+ 56 353 ± 693 12,118 ,+ 7,041 13,469 +_ 7,629 
Carmeda 617 ,+ 175 676 ± 222 980 ,+ 323 944 _+ 307 
1 U/ml Control 333 ± 94 3,997 _+ 3,122 31,466 ± 18,817 29,916 _+ 16,293 
Carmeda 779 ± 236 588 _+ 191 2,615 ± 968 3,035 + 1,529 
Vaiues presented are means _+ standard error of the mean, expressed in picograms per milliliter. For all time points, n = 6. 
counts of 5.5 _+ 0.6 × 103/ram 3 noted at 2 hours (p < 
0.05 vs control). 
When blood was recirculated with 1 U/ml heparin 
in the control group (Fig. 4, B), a relative leukope- 
nia was observed over time, with counts decreasing 
from 6.8 _+ 0.4 × 103/mm 3 to 4.2 _+ 0.3 × 10s/ram 3 
at 2 hours. In contrast, heparin coating maintained 
circulating leukocyte counts (baseline: 5.9 _+ 0.4 × 
103/mm 3 and 2 hours: 5.2 _+ 0.4 × 103/mm3;p < 0.05 
vs control). 
When blood containing 5 U/ml heparin was recir- 
culated through uncoated circuits, plasma neutro- 
phil elastase (Fig. 5) rose from an initial value of 
0.06 _+ 0.02 ng/ml to 0.72 _+ 0.29 ng/ml at 2 hours. In 
comparison, heparin surface treatment reduced 
neutrophil elastase release, with a baseline of 0.05 _+ 
0.03 ng/ml increasing to only 0.33 _+ 0.23 ng/ml at 2 
hours (p < 0.05 vs control). 
Neutrophil elastase levels in the control group at 
reduced heparin dose (1 U/ml) rose from 0.06 -- 
0.02 ng/ml to 0.85 -+ 0.08 ng/ml at 2 hours. When 
circuits were coated with heparin, there was a 
significant reduction in neutrophil elastase release 
(baseline: 0.07 _+ 0.01 ng/ml; 2 hours: 0.20 _+ 0.05 
ng/ml; p < 0.05 vs control). 
Thus surface treatment was found to reduce both 
leukocyte depletion and elastase release at both 
doses of heparin. 
C3a. Although other investigators have demon- 
strated that complement generation may be mani- 
fested by the formation of terminal complement 
complexes, a2the validity of C3a measurement asan 
indicator of complement activation appears to be 
well founded. 23 
C3a (Fig. 6) increased from an initial level of 
240 _+ 67 ng/ml to 5630 _+ 964 ng/ml at 2 hours in 
control circuits with 5 U/ml heparin doses. In the 
treatment group, C3a levels also increased from a 
baseline of 130 _+ 13 ng/ml to 3933 _+ 797 ng/ml at 2 
hours (p > 0.05 vs control). 
With reduced heparin (1 U/ml), the untreated 
circuits demonstrated a profound increase in C3a 
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Fig. 4. A and B, Circulating leukocyte count. Mean leukocyte (WBC) counts (mean _+ standard error of 
the mean) from whole blood are plotted against ime and expressed × 103/ram 3. Otherwise legend is 
identical to that of Fig. 1. 
production. The baseline value rose from 175 + 29 
ng/ml to 14,410 _+ 3,558 ng/ml after 2 hours of 
recirculation. This response was significantly atten- 
uated in the heparin-coated circuits. Before recircu- 
lation, C3a measured 166 _+ 40 ng/ml, increasing to 
only 3053 _+ 1039 ng/m! by 2 hours (p < 0.05 vs 
control). 
Thus surface treatment markedly reduced C3a 
generation at the lower dose of circulating heparin. 
Fibrinopeptide A. At full heparinization (5 
U/ml), fibrinopeptide A levels (Fig. 7) remained low 
in both the untreated and coated circuits (88 _+ 49 
ng/ml control vs 68 _+ 48 ng/ml coated at 2 hours). 
Importantly, fibrinopeptide A levels with 1 U/ml 
heparin doses were markedly elevated in both the 
control and treated circuits at 2 hours (793 _+ 337 
ng/ml control vs 563 _+ 459 ng/ml coated; p > 0.05). 
These data indicate that the surface treatment did 
not provide effective anticoagulant activity in this in 
vitro model. 
Discussion 
Effects on platelets. The artificial surface of car- 
diopulmonary bypass circuits is a potent stimulus for 
platelet activation, as has been described in both 
clinical24, 25 and experimental studies. 1°' 26 Platelet 
adhesion to the surface and subsequent activation 
are thought to be mediated by specific receptor- 
ligand interactions of the platelet membrane with 
surface-bound fibrinogen, a7 Moreover, the platelet 
1080 Korn et al. 
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Fig. 5. Neutrophil elastase. Mean levels of plasma elastase-%-proteinase inhibitor complex (mean + 
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Fig. 6. Complement C3a des Arg. Mean plasma C3a des Arg levels (mean _+ standard error of the mean) 
are plotted against time and expressed in nanograms per milliliter × 10 -1. Otherwise legend is identical 
to that of Fig. 1. 
membrane glycoprotein IIb/IIIa complex is the re- 
ceptor responsible for adhesion. 2s Platelet activa- 
tion is customarily viewed as an organized process 
resulting in shape change, granule release, and 
thromboxane generation. Recent data have sug- 
gested, however, that the platelet release reaction 
observed in the extracorporeal circuit may be the 
result of shear force-induced destruction of surface 
adherent platelets. 29 
In these experiments, the heparin-bonded surface 
attenuated early platelet depletion and markedly 
reduced platelet granule release, as reflected in the 
measured levels of platelet factor 4 and/3-thrombo- 
globulin• This effect was observed at both levels of 
heparinization. Although there was a tendency to- 
ward reduced generation of thromboxanes in both 
groups of coated circuits, this was more pronounced 
with the lower dose of heparin. Interestingly, the 
surface treatment had a transient effect on platelet 
adhesion, whereas it caused a sustained reduction in 
platelet granule release. This uncoupling of adhe- 
sion and degranulation was observed by Musial and 
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Fig. 7. Fibrinopeptide A. Mean plasma fibrinopeptide A levels (mean _+ standard error of the mean) are 
plotted against time and expressed in nanograms per milliliter. Otherwise legend is identical to that of Fig. 1. 
associates 29when disintegrins were introduced into 
the extracorporeal circuit. It may be the case that 
altered surface composition has at least a transient 
effect on the plasma protein coat. 3° This, in turn, 
may affect the time course and extent of platelet 
adhesion and activation in this model. Artificial 
surface exposure is known to induce stereotypic 
changes in the platelet receptor population, with 
demonstrable effects on both the glycoprotein IIb/ 
I l ia complex and the o~2-adrenergic receptor. 31 Thus 
an altered surface may present a quantitatively, if 
not qualitatively, different stimulus to the platelet 
population, thereby fundamentally altering the dy- 
namic platelet-surface interaction. 
Other investigators have reported that heparin 
surface treatment had a sustained impact on platelet 
adhesion during in vitro surface contact. 32 It is 
possible that differences in recirculation tempera- 
ture and blood dilution may account for the differ- 
ences observed in the circulating platelet count in 
our experiments compared with those of Videm and 
associates. 32
It is also noteworthy that the onset of platelet 
dysfunction, as assessed by ADP-induced aggrega- 
tion, was delayed in these studies by surface treat- 
ment. This effect was apparent at the higher concen- 
tration of heparin. Given that this in vitro model of 
cardiopulmonary b pass presents a substantial inju- 
rious stimulus to platelets, these data suggest a 
promising role for surface modification in reducing 
platelet activation. 
Effects on the inflammatory response. Activated 
leukocytes have a central role in the pathophysiol- 
ogy of cardiopulmonary b pass. The most common 
complication is prolonged ventilator dependence 
and is known to result from lung microvascular 
injury effected by the neutrophil. 5' 6, 33 Contact sys- 
tem activation generates both complement 34' 35 and 
kallikrein. 36'37 Levels of C3a are known to rise 
progressively in blood during exposure to oxygen- 
ators. 3s'39 Furthermore, C5a, C3b, and kallikrein 
directly activate neutrophils, 34thereby establishing 
the nexus between the cellular and humoral limbs of 
the systemic inflammatory response. Neutrophil ac- 
tivation in this context is characterized by release of 
elastase, a serine protease contained in the "azuro- 
philic" granule, and release of lactoferrin, a "specif- 
ic" granule marker9 3'4o 
This model of simulated cardiopulmonary b pass 
manifested a mild, but consistent decrease in circu- 
lating leukocyte count, a change that was more 
pronounced at reduced heparin concentrations. The 
surface treatment reduced leukocyte depletion, with 
a greater impact observed at the lower heparin 
concentration. Elastase release was used as a 
marker of neutrophil activation and was found to be 
significantly reduced at both concentrations of hep- 
arin in the experimental circuits. In addition, al- 
though the surface alteration reduced C3a genera- 
tion, a significant effect was observed only at the 
lower level of circulating heparin. Taken together, 
these data suggest hat surface treatment reduced 
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leukocyte activation independent of its effects on 
C3a production. Indeed, reduction in complement 
activation in this in vitro model may be solely 
dependent on heparin concentration, whether in 
fluid phase or bound to the surface, and is supported 
by the literature. 41-43 This is in contrast o clinical 
data reflecting increased complement generation 
after the start of cardiopulmonary b pass despite 
requisite use of heparin. 6'35 The differences are 
most likely related to in vivo factors that are not 
present in our closed in vitro model. Other humoral 
mediators, such as kallikrein, may therefore pro- 
mote leukocyte activation in this model. 44 
Videm and colleagues 22have proposed that sur- 
face biocompatibility might best be assessed by the 
use of indices of leukocyte activation. This recog- 
nizes that the leukocyte, as mediator of microvascu- 
lar injury, serves as an end point of the complement 
and kallikrein systems in the manifestation f the 
inflammatory esponse. 44In addition, platelet acti- 
vation during blood surface contact may stimulate 
leukocytes, in that activated platelets have been 
shown to adhere to both monocytes and neutrophils 
by a specifc receptor. 45 
Although heparin surface treatment was origi- 
nally developed to reduce the requirement for ex- 
ogenous heparin administration, the data from these 
studies and other investigations indicate that the 
surface has a consistent effect on complement and 
leukocyte activation. 23' 32, 46, 47 Our results suggest 
that the antiinflammatory activity of the Carmeda 
surface treatment is not contingent on a reduction in 
the exogenous heparin dose. 
Effects on blood coagulation. Since the develop- 
ment of the first extracorporeal circuit, the most 
significant clinical problems after cardiopulmonary 
bypass have been related to hemorrhage, a Heparin 
coating of the circuit was proposed as a nonthrom- 
bogenic interface that would reduce reliance on 
high-dose xogenous heparin during blood contact 
with the artificial surface. This, in turn, would be 
expected to limit perioperative blood loss and sub- 
sequent transfusion requirements, as well as prevent 
unnecessary reoperation. 4s-5° Initial attempts at 
heparin surface bonding were disappointing, with no 
surface tested heretofore demonstrating any real 
anticoagulant activity, s Although studies by von 
Segesser and associates 51's2 have used heparin- 
coated oxygenators and pumps without exogenous 
heparin administration, these studies were per- 
formed in animals and are not entirely relevant to 
clinical cardiopulmonary bypass. The Carmeda 
treatment is the result of new bonding technology, 
which is thought o provide good active site orien- 
tation of the heparin molecule, relative to the fluid 
component of the blood. It has also been demon- 
strated to have in vitro thrombin-inhibiting activity. 8
The data obtained in these experiments, using 
human blood, indicate that the Carmeda surface 
treatment did not affect generation offibrinopeptide 
A at either dose of heparin. Importantly, this is the 
only study in which the anticoagulant effects of 
surface modification are assessed with human blood 
using a sensitive index of fibrinogen cleavage, in the 
absence of full heparinization. Although some clin- 
ical data indicate that the Duraflo heparin treatment 
(Baxter Healthcare Corp., Irvine, Calif.) reduced 
requirements for protamine administration and 
blood transfusion, with reduction in fibrinolysis as 
well, the study reporting these data used aprotinin in 
the low heparin treatment group but not in the 
group of patients receiving full heparinization. 49 In 
addition, Jones and colleagues 53recently published 
results of a clinical trial using the Carmeda surface 
for cardiopulmonary b pass in patients at high risk 
for systemic heparinization. They were able to re- 
duce exogenous administration f heparin and con- 
sequently protamine without any overt thrombotic 
complications, although fibrinopeptide A levels 
were not measured in this study. 
We did not observe any evidence of gross clot in 
the circuits in which a reduced heparin dose was 
used, with or without the Carmeda surface treat- 
ment. This fact, in concert with the fibrinopeptide A 
data, would suggest hat the absence of adverse 
clotting noted in clinical studies using heparin sur- 
face treatment may not be attributable to the hep- 
arin coating per se. 48-5°' 54, 55 These clinical studies 
have, of course, lacked the control group using 
reduced heparinization i the absence of surface 
modification. In addition, the question israised as to 
whether this surface treatment has effective antico- 
agulant activity when a large surface area, such as an 
oxygenator, constitutes the thrombogenic stimulus. 
Our experiments directly address this question with 
human blood in a well-established model of cardio- 
pulmonary bypass. 
Summary 
The data indicate that heparin surface treatment 
had a significant impact on the extent and time 
course of several indices of platelet and leukocyte 
activation. Surface treatment ameliorated formed 
blood element injury, with effects noted, generally, 
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at full or  reduced  hepar in izat ion.  The  data do not  
ind icate that  sur face t reatment  reduced  f ibr inogen 
cleavage. Thus the Carmeda surface t reatment  did 
not  exhibit  ant icoagulant  efficacy, yet it did mani fest  
signif icant ant i in f lammatory  activity in this model .  
Our  results, a long with those obta ined  by o ther  
invest igators eva luat ing the most  recent  generat ion  
of  hepar in  surface t reatments ,  cont inue  to va l idate 
the concept  that  sur face modi f i cat ion  may yet pro-  
v ide a more  b iocompat ib le  surface than has thus far 
been  real ized.  Perhaps  surface appl icat ion of  inhib- 
itors of  contact  system init iat ion, such as factor  X I I ,  
as suggested by Edmunds ,  Niewiarowski ,  and Col-  
man,  44 may yet prov ide  more  mean ingfu l  contro l  of  
the sur face- induced in f lammatory  response.  
We express our gratitude to Lucretia Rena Smith for 
assistance with the manuscript preparation. 
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